|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/14/22 CASI Pharmaceuticals, Inc. 10-Q 9/30/22 74:7.2M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.67M
2: EX-10.1 Material Contract HTML 289K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 25K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 26K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 22K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 23K
12: R1 Document and Entity Information HTML 74K
13: R2 Unaudited Condensed Consolidated Balance Sheets HTML 126K
14: R3 Unaudited Condensed Consolidated Balance Sheets HTML 43K
(Parenthetical)
15: R4 Unaudited Condensed Consolidated Statements of HTML 147K
Operations and Comprehensive Loss
16: R5 Unaudited Condensed Consolidated Statements of HTML 81K
Stockholders' Equity
17: R6 Unaudited Condensed Consolidated Statements of HTML 141K
Cash Flows
18: R7 Description of Business HTML 27K
19: R8 License and Distribution Agreements HTML 41K
20: R9 Summary of Significant Accounting Policies HTML 26K
21: R10 Revenue Related Information HTML 25K
22: R11 Investment in Equity Securities, at Fair Value and HTML 192K
Long-term Investments
23: R12 Inventories HTML 22K
24: R13 Property, Plant and Equipment HTML 41K
25: R14 Leases HTML 63K
26: R15 Accrued and Other Current Liabilities, and Other HTML 52K
Liabilities
27: R16 Bank Borrowings HTML 21K
28: R17 Redeemable Noncontrolling Interest HTML 38K
29: R18 Stockholders' Equity HTML 31K
30: R19 Net Loss Per Share HTML 58K
31: R20 Stock-Based Compensation HTML 38K
32: R21 Income Taxes HTML 25K
33: R22 Fair Value Measurements HTML 106K
34: R23 Related Party Transactions HTML 24K
35: R24 Commitments and Contingencies HTML 27K
36: R25 Subsequent Events HTML 23K
37: R26 Summary of Significant Accounting Policies HTML 31K
(Policies)
38: R27 Investment in Equity Securities, at Fair Value and HTML 189K
Long-term Investments (Tables)
39: R28 Property, Plant and Equipment (Tables) HTML 39K
40: R29 Leases (Tables) HTML 63K
41: R30 Accrued and Other Current Liabilities, and Other HTML 51K
Liabilities (Tables)
42: R31 Redeemable Noncontrolling Interest (Tables) HTML 37K
43: R32 Net Loss Per Share (Tables) HTML 56K
44: R33 Stock-Based Compensation (Tables) HTML 36K
45: R34 Fair Value Measurements (Tables) HTML 99K
46: R35 Description of Business (Details) HTML 30K
47: R36 License and Distribution Agreements (Details) HTML 112K
48: R37 Investment in Equity Securities, at Fair Value and HTML 32K
Long-term Investments - Summary of Investments
(Details)
49: R38 Investment in Equity Securities, at Fair Value and HTML 58K
Long-term Investments - Summary of Long-term
investments (Details)
50: R39 Investment in Equity Securities, at Fair Value and HTML 57K
Long-term Investments (Details)
51: R40 Inventories (Details) HTML 25K
52: R41 Property, Plant and Equipment (Details) HTML 36K
53: R42 Leases - (Details) HTML 39K
54: R43 Leases - Right of Use Assets and Liabilities HTML 36K
(Details)
55: R44 Leases - Supplemental Cash Flow (Details) HTML 25K
56: R45 Leases - Future Undiscounted Cash Flows (Details) HTML 38K
57: R46 Accrued and Other Current Liabilities, and Other HTML 50K
Liabilities (Details)
58: R47 Bank Borrowings (Details) HTML 36K
59: R48 Redeemable Noncontrolling Interest - Changes in HTML 30K
Redeemable Noncontrolling Interest (Details)
60: R49 Stockholders' Equity (Details) HTML 51K
61: R50 Net Loss Per Share (Details) HTML 24K
62: R51 Net Loss Per Share - Basic and diluted net loss HTML 54K
per share computation (Details)
63: R52 Stock-Based Compensation - Compensation Expense HTML 29K
(Details)
64: R53 Income Taxes (Details) HTML 22K
65: R54 Fair Value Measurements - Financial and HTML 47K
Non-Financial Assets and Liabilities (Details)
66: R55 Fair Value Measurements (Details) HTML 31K
67: R56 Related Party Transactions (Details) HTML 33K
68: R57 Commitments and Contingencies (Details) HTML 47K
69: R58 Subsequent Event (Details) HTML 25K
72: XML IDEA XML File -- Filing Summary XML 132K
70: XML XBRL Instance -- casi-20220930x10q_htm XML 1.82M
71: EXCEL IDEA Workbook of Financial Reports XLSX 117K
8: EX-101.CAL XBRL Calculations -- casi-20220930_cal XML 163K
9: EX-101.DEF XBRL Definitions -- casi-20220930_def XML 475K
10: EX-101.LAB XBRL Labels -- casi-20220930_lab XML 850K
11: EX-101.PRE XBRL Presentations -- casi-20220930_pre XML 719K
7: EX-101.SCH XBRL Schema -- casi-20220930 XSD 158K
73: JSON XBRL Instance as JSON Data -- MetaLinks 332± 503K
74: ZIP XBRL Zipped Folder -- 0001558370-22-017615-xbrl Zip 320K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM i 10-Q
| |
i ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| |
For the quarterly period ended i September 30, 2022 | |
| |
i ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ___________ to _____________.
Commission file number i 0-20713
i CASI PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| |
i Delaware | i 58-1959440 |
(State or other jurisdiction of | (I.R.S. Employer Identification No.) |
incorporation or organization) | |
i 9620 Medical Center Drive, i Suite 300
i Rockville, i Maryland
(Address of principal executive offices)
i 20850
(Zip code)
( i 240) i 864-2600
(Registrant’s telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of exchange on which registered |
i Common Stock |
| i CASI |
| i Nasdaq Capital Market |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
YES ⌧ NO ◻
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
YES ⌧ NO ◻
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | |
Large accelerated filer ◻ | Accelerated filer ◻ | i Non-accelerated filer þ | Smaller reporting company i ☑ |
| | | Emerging growth company i ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻
Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES i ☐ NO ⌧
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the most recent practicable date.
| | |
Class |
| Outstanding at November 8, 2022 |
Common Stock $.01 Par Value |
| i 13,606,130 |
CASI PHARMACEUTICALS, INC.
| | ||
|
| PAGE | |
| 4 | ||
| | | |
| 4 | ||
| | ||
Unaudited Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 | | 4 | |
| | ||
| 5 | ||
| | ||
| 6 | ||
| | ||
| 8 | ||
| | ||
Notes to Unaudited Condensed Consolidated Financial Statements | | 9 | |
| | ||
Management’s Discussion and Analysis of Financial Condition and Results of Operations | | 23 | |
| | ||
| 28 | ||
| | ||
| 28 | ||
| | ||
| 29 | ||
| | | |
| 29 | ||
| | ||
| 29 | ||
| | ||
| 29 | ||
| | ||
| 29 | ||
| | ||
| 29 | ||
| | ||
| 29 | ||
| | ||
| 30 | ||
| | ||
| 31 | ||
2
TRADEMARKS AND SERVICE MARKS
We own or have rights to trademarks and trademark applications for use in connection with the operation of our business, including, but not limited to, CASI and CASI PHARMACEUTICALS. All other trademarks appearing in this Quarterly Report on Form 10-Q that are not identified as marks owned by us are the property of their respective owners.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This report contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements also may be included in other statements that we make. All statements that are not descriptions of historical facts are forward-looking statements. These statements can generally be identified by the use of forward-looking terminology such as “believes,” “expects,” “intends,” “may,” “will,” “should,” or “anticipates” or similar terminology. These forward-looking statements include, among others, statements regarding the timing of our commercial launch of products, clinical trials, our cash position and future expenses, and our future revenues.
Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on The Nasdaq Capital Market if we fail to satisfy applicable continued listing standards, including compliance with the Nasdaq bid price rule; the risk in relation to being identified as a “Commission Identified Issuer”; the volatility in the market price of our common stock; the outbreak of the COVID-19 pandemic and its effects on global markets and supply chains; the risk of substantial dilution of existing stockholders in future stock issuances; the difficulty of executing our business strategy on a global basis including China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; legal or regulatory developments in China that adversely affect our ability to operate in China; our lack of experience in manufacturing products and uncertainty about our resources and capabilities to do so on a clinical or commercial scale; risks relating to the commercialization, if any, of our products and proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); our inability to predict when or if our product candidates will be approved for marketing by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), National Medical Products Administration (NMPA), or other regulatory authorities; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; the risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the risks associated with our product candidates, and the risks associated with our other early-stage products under development; the risk that result in preclinical and clinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; our ability to protect our intellectual property rights; the lack of success in the clinical development of any of our products; and our dependence on third parties; the risks related to our dependence on Juventas to conduct the clinical development of CNCT19 and to partner with us to co-market CNCT19; risks related to our dependence on Juventas to ensure the patent protection and prosecution for CNCT19; risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); risks relating to interests of our largest stockholders and our Chairman and CEO that differ from our other stockholders; and risks related to the development of a new manufacturing facility by CASI Pharmaceuticals (Wuxi) Co., Ltd. (“CASI Wuxi”). Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition.
We caution investors that actual results or business conditions may differ materially from those projected or suggested in forward-looking statements as a result of various factors including, but not limited to, those described above and in Section IA, “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and our other filings with the Securities and Exchange Commission (“SEC”). We cannot assure you that we have identified all the factors that create uncertainties. Moreover, new risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all risks on our business or the extent to which any risk, or combination of risks, may cause actual results to differ from those contained in any forward-looking statements. Readers should not place undue reliance on forward-looking statements, which only relate to events or information as of the date made. We undertake no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances after the date they are made or to reflect the occurrence of unanticipated events. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission (“SEC”), which are available at www.sec.gov.
3
PART I. FINANCIAL INFORMATION
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS
CASI Pharmaceuticals, Inc.
Unaudited Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
| | | | | | | |
| | | | | |
| |
|
|
|
| ||||
ASSETS |
| |
|
| |
| |
Current assets: |
| |
|
| |
| |
Cash and cash equivalents | | $ | i 26,742 | | $ | i 38,704 | |
Restricted cash | | | i 2,500 | | | — | |
Investment in equity securities, at fair value | |
| i 6,309 | |
| i 9,868 | |
Accounts receivable, net of $ i i 0 / allowance for doubtful accounts | | | i 12,560 | | | i 9,803 | |
Inventories | | | i 5,773 | | | i 1,907 | |
Prepaid expenses and other | |
| i 1,728 | |
| i 1,688 | |
Total current assets | |
| i 55,612 | |
| i 61,970 | |
| | | | | | | |
Property, plant and equipment, net | |
| i 13,867 | |
| i 12,712 | |
Intangible assets, net | |
| i 10,049 | |
| i 12,203 | |
Long-term investments | | | i 39,780 | | | i 40,128 | |
Right of use assets | | | i 7,666 | | | i 9,107 | |
Other assets | |
| i 932 | |
| i 2,178 | |
Total assets | | $ | i 127,906 | | $ | i 138,298 | |
| | | | | | | |
LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND STOCKHOLDERS’ EQUITY | |
|
| |
|
| |
Current liabilities: | |
|
| |
|
| |
Accounts payable | | $ | i 3,098 | | $ | i 4,789 | |
Bank borrowings | | | i 3,000 | | | — | |
Accrued and other current liabilities | |
| i 23,651 | |
| i 8,397 | |
Total current liabilities | |
| i 29,749 | |
| i 13,186 | |
| | | | | | | |
Deferred income | |
| i 2,488 | |
| i 2,828 | |
Other liabilities | |
| i 12,455 | |
| i 14,325 | |
Total liabilities | |
| i 44,692 | |
| i 30,339 | |
| | | | | | | |
Commitments and contingencies | |
|
| |
|
| |
| | | | | | | |
Redeemable noncontrolling interest, at redemption value | | | i 21,503 | | | i 23,457 | |
| | | | | | | |
Stockholders’ equity: | |
|
| |
|
| |
Preferred stock, $ i i 1.00 / par value: i i 5,000,000 / shares authorized and i i 0 / shares issued and | |
| i — | |
| i — | |
outstanding | | | | | | | |
Common stock, $ i i 0.01 / par value: | | | | | | | |
i i 250,000,000 / shares authorized at September 30, 2022 and December 31, 2021 | |
| | |
| | |
i 13,733,459 shares and i 13,987,578 shares issued at September 30, 2022 and December 31, 2021, respectively; | | | | | | | |
i 13,606,130 shares and i 13,979,624 shares outstanding at September 30, 2022 and December 31, 2021, respectively | | | i 1,373 | | | i 1,399 | |
Additional paid-in capital | |
| i 696,213 | |
| i 694,826 | |
Treasury stock, at cost: i 127,329 shares and i 7,954 shares held at September 30, 2022 and December 31, 2021 | |
| ( i 9,068) | |
| ( i 8,034) | |
Accumulated other comprehensive income | |
| ( i 1,951) | |
| i 1,954 | |
Accumulated deficit | |
| ( i 624,856) | |
| ( i 605,643) | |
Total stockholders’ equity | |
| i 61,711 | |
| i 84,502 | |
Total liabilities, redeemable noncontrolling interest and stockholders' equity | | $ | i 127,906 | | $ | i 138,298 | |
The accompanying notes are an integral part of these consolidated financial statements.
4
CASI Pharmaceuticals, Inc.
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
| | | | | | | | | | | | | |
| | Three Months Ended September 30 |
| Nine Months Ended September 30 |
| ||||||||
| | 2022 | | 2021 | | 2022 | | 2021 | | ||||
Revenues: | | | | | | | | | | | | | |
Product sales | | $ | i 10,213 | | | i 8,075 | | $ | i 27,788 | | $ | i 20,900 | |
Lease income from a related party | |
| — | | | i 37 | |
| i 60 | |
| i 110 | |
Total revenues | | | i 10,213 | | | i 8,112 | | | i 27,848 | | | i 21,010 | |
| | | | | | | | | | | | | |
Costs of revenues | | | i 4,247 | | | i 3,417 | | | i 11,555 | | | i 8,757 | |
| | | | | | | | | | | | | |
Gross Profit | | | i 5,966 | | | i 4,695 | | | i 16,293 | | | i 12,253 | |
| | | | | | | | | | | | | |
Operating expenses: | | |
| |
|
| |
|
| | |
| |
Research and development | | | i 3,905 | | | i 2,895 | | | i 11,748 | | | i 10,408 | |
General and administrative | | | i 4,849 | | | i 5,259 | | | i 15,694 | | | i 16,249 | |
Selling and marketing | |
| i 3,566 | | | i 3,433 | | | i 10,241 | | | i 9,508 | |
Acquired in-process research and development | | | i — | | | i — | | | i — | | | i 6,555 | |
Total operating expenses | |
| i 12,320 | |
| i 11,587 | |
| i 37,683 | |
| i 42,720 | |
| | | | | | | | | | | | | |
Loss from operations | | | ( i 6,354) | | | ( i 6,892) | | | ( i 21,390) | | | ( i 30,467) | |
| | | | | | | | | | | | | |
Non-operating income (expense): | | | | | | | | | | | | | |
Interest (expense)/income, net | |
| ( i 13) | | | i 79 | | | i 101 | | | i 261 | |
Other income | | | i 11 | | | i 487 | | | i 60 | | | i 540 | |
Foreign exchange gains/(losses) | | | i 637 | | | ( i 6) | | | i 2,325 | | | i 289 | |
Change in fair value of investments | |
| i 696 | | | ( i 3,687) | | | ( i 2,012) | | | ( i 205) | |
Impairment loss of long-term investments | | | — | | | — | | | — | | | ( i 865) | |
Loss before income tax expense | | | ( i 5,023) | | | ( i 10,019) | | | ( i 20,916) | | | ( i 30,447) | |
Income tax expense | | | — | | | — | | | — | | | — | |
Net loss | | | ( i 5,023) | | | ( i 10,019) | | | ( i 20,916) | | | ( i 30,447) | |
Less: loss attributable to redeemable noncontrolling interest | | | ( i 738) | | | ( i 314) | | | ( i 1,703) | | | ( i 980) | |
Accretion to redeemable noncontrolling interest redemption value | | | i 916 | | | i 519 | | | i 2,264 | | | i 1,586 | |
Net loss attributable to CASI Pharmaceuticals, Inc. | | $ | ( i 5,201) | | $ | ( i 10,224) | | $ | ( i 21,477) | | $ | ( i 31,053) | |
| | | | | | | | | | | | | |
Net loss per share (basic and diluted) | | $ | ( i 0.38) | | $ | ( i 0.73) | | $ | ( i 1.57) | | $ | ( i 2.30) | |
Weighted average number of common stock outstanding (basic and diluted) | |
| i 13,606,130 | | | i 13,979,636 | | | i 13,668,553 | | | i 13,486,024 | |
| | | | | | | | | | | | | |
Comprehensive loss: | |
| | |
|
| |
| | |
|
| |
Net loss | | $ | ( i 5,023) | | $ | ( i 10,019) | | $ | ( i 20,916) | | $ | ( i 30,447) | |
Foreign currency translation adjustment | |
| ( i 3,127) | | | i 15 | | | ( i 6,420) | | | i 848 | |
Total comprehensive loss | | $ | ( i 8,150) | | $ | ( i 10,004) | | $ | ( i 27,336) | | $ | ( i 29,599) | |
Less: Comprehensive loss attributable to redeemable noncontrolling interest | | | ( i 2,074) | | | ( i 309) | | | ( i 4,218) | | | ( i 712) | |
Comprehensive loss attributable to common stockholders | | $ | ( i 6,076) | | $ | ( i 9,695) | | $ | ( i 23,118) | | $ | ( i 28,887) | |
The accompanying notes are an integral part of these consolidated financial statements.
5
CASI Pharmaceuticals, Inc.
Unaudited Condensed Consolidated Statements of Stockholders’ Equity
(In thousands, except share data)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | Accumulated | | | | | | | |
| | | | | | | | | | | | | Additional | | | | Other | | | | | | | |||
| Preferred Stock | | Common Stock | | Paid-in | | Treasury | | Comprehensive | | Accumulated | | | | ||||||||||||
| Shares |
| Amount |
| Shares |
| Amount |
| Capital |
| Stock |
| Income /(Loss) |
| Deficit |
| Total | |||||||||
Balance at December 31, 2021 | | i — | | $ | i — | | | i 13,979,636 | | $ | i 1,399 | | $ | i 694,826 | | $ | ( i 8,034) | | $ | i 1,954 | | $ | ( i 605,643) | | $ | i 84,502 |
Repurchase and retirement of common stock | | — | | | — | | | ( i 373,506) | | | ( i 26) | | | ( i 1,940) | | | ( i 1,034) | | | | | | | | | ( i 3,000) |
Stock-based compensation expense, net of forfeitures |
| i — | |
| i — | |
| i — | | | i — | | | i 1,908 | | | i — | | | i — | | | i — | |
| i 1,908 |
Foreign currency translation adjustment | | i — | | | i — | | | i — | | | i — | | | i — | | | i — | | | i 175 | | | i — | | | i 175 |
Net loss attributable to CASI Pharmaceuticals, Inc. |
| i — | |
| i — | |
| i — | | | i — | | | ( i 613) | | | i — | | | i — | | | ( i 7,983) | |
| ( i 8,596) |
Balance at March 31, 2022 |
| — | | $ | — | |
| i 13,606,130 | | $ | i 1,373 | |
| i 694,181 | |
| ( i 9,068) | | | i 2,129 | |
| ( i 613,626) | |
| i 74,989 |
Stock-based compensation expense, net of forfeitures | | — | | | — | | | — | | | — | | | i 1,923 | | | i — | | | i — | | | i — | | | i 1,923 |
Foreign currency translation adjustment | | — | | | — | | | — | | | — | | | — | | | i — | | | ( i 2,289) | | | i — | | | ( i 2,289) |
Net loss attributable to CASI Pharmaceuticals, Inc. | | — | | | — | | | — | | | — | | | ( i 735) | | | i — | | | i — | | | ( i 6,945) | | | ( i 7,680) |
Balance at June 30, 2022 |
| — | | $ | — | |
| i 13,606,130 | | $ | i 1,373 | | $ | i 695,369 | | $ | ( i 9,068) | | $ | ( i 160) | | $ | ( i 620,571) | | $ | i 66,943 |
Stock-based compensation expense, net of forfeitures | | — | | | — | | | — | | | — | | | i 1,760 | | | i — | | | i — | | | i — | | | i 1,760 |
Foreign currency translation adjustment | | — | | | — | | | — | | | — | | | — | | | i — | | | ( i 1,791) | | | i — | | | ( i 1,791) |
Net loss attributable to CASI Pharmaceuticals, Inc. | | — | | | — | | | — | | | — | | | ( i 916) | | | i — | | | i — | | | ( i 4,285) | | | ( i 5,201) |
Balance at September 30, 2022 |
| i — | | $ | i — | |
| i 13,606,130 | | $ | i 1,373 | | $ | i 696,213 | | $ | ( i 9,068) | | $ | ( i 1,951) | | $ | ( i 624,856) | | $ | i 61,711 |
The accompanying notes are an integral part of these consolidated financial statements.
6
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | Accumulated | | | | | | | |
| | | | | | | | | | | | | Additional | | | | Other | | | | | | | |||
| Preferred Stock | | Common Stock | | Paid-in | | Treasury | | Comprehensive | | Accumulated | | | | ||||||||||||
| Shares |
| Amount |
| Shares |
| Amount |
| Capital |
| Stock |
| Loss |
| Deficit |
| Total | |||||||||
Balance at December 31, 2020 | | i — | | $ | i — | | | i 12,394,271 | | $ | i 1,240 | | $ | i 658,246 | | $ | ( i 8,034) | | $ | i 589 | | $ | ( i 570,501) | | $ | i 81,540 |
Issuance of common stock pursuant to financing agreements | | — | | | — | | | i 1,585,365 | |
| i 159 | |
| i 32,341 | |
| — | | | — | |
| — | | | i 32,500 |
Stock issuance costs |
| i — | |
| i — | |
| i — | | | i — | | | ( i 2,019) | | | i — | | | i — | | | i — | |
| ( i 2,019) |
Stock-based compensation expense, net of forfeitures | | i — | | | i — | | | i — | |
| i — | |
| i 1,998 | |
| i — | | | i — | |
| i — | | | i 1,998 |
Foreign currency translation adjustment |
| i — | |
| i — | |
| i — | | | i — | | | i — | | | i — | | | ( i 104) | | | i — | |
| ( i 104) |
Net loss attributable to CASI Pharmaceuticals, Inc. |
| i — | |
| i — | |
| i — | |
| i — | |
| ( i 548) | |
| i — | | | i — | |
| ( i 13,335) | |
| ( i 13,883) |
Balance at March 31, 2021 |
| — | | $ | — | |
| i 13,979,636 | | $ | i 1,399 | |
| i 690,018 | |
| ( i 8,034) | | | i 485 | |
| ( i 583,836) | |
| i 100,032 |
Stock-based compensation expense, net of forfeitures | | — | | | — | | | — | | | — | | | i 1,040 | | | — | | | — | | | — | | | i 1,040 |
Foreign currency translation adjustment | | — | | | — | | | — | | | — | | | — | | | — | | | i 674 | | | — | | | i 674 |
Net loss attributable to CASI Pharmaceuticals, Inc. | | — | | | — | | | — | | | — | | | ( i 519) | | | — | | | — | | | ( i 6,427) | | | ( i 6,946) |
Balance at June 30, 2021 |
| — | | $ | — | |
| i 13,979,636 | | $ | i 1,399 | | $ | i 690,539 | | $ | ( i 8,034) | | $ | i 1,159 | | $ | ( i 590,263) | | $ | i 94,800 |
Stock-based compensation expense, net of forfeitures | | — | | | — | | | — | | | — | | | i 2,021 | | | — | | | — | | | — | | | i 2,021 |
Foreign currency translation adjustment | | — | | | — | | | — | | | — | | | — | | | — | | | i 10 | | | — | | | i 10 |
Net loss attributable to CASI Pharmaceuticals, Inc. | | — | | | — | | | — | | | — | | | ( i 519) | | | — | | | — | | | ( i 9,705) | | | ( i 10,224) |
Balance at September 30, 2021 |
| i — | | $ | i — | |
| i 13,979,636 | | $ | i 1,399 | | $ | i 692,041 | | $ | ( i 8,034) | | $ | i 1,169 | | $ | ( i 599,968) | | $ | i 86,607 |
The accompanying notes are an integral part of these consolidated financial statements.
7
CASI Pharmaceuticals, Inc.
Unaudited Condensed Consolidated Statements of Cash Flows
(In thousands)
| | | | | | | |
| | Nine Months Ended |
| ||||
| | | | | | ||
|
|
|
| ||||
CASH FLOWS FROM OPERATING ACTIVITIES |
| |
|
| |
| |
Net loss | | $ | ( i 20,916) | | | ( i 30,447) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | | | |
Depreciation for property, plant and equipment | |
| i 567 | | | i 393 | |
Amortization of intangible assets | |
| i 965 | | | i 1,009 | |
Reduction in the carrying amount of the right-of-use assets | | | i 890 | | | i 1,031 | |
Loss on disposal of property, plant and equipment | |
| — | | | i 65 | |
Government grant as a result of loan forgiveness | | | — | | | ( i 472) | |
Stock-based compensation expense | |
| i 5,591 | | | i 5,059 | |
Acquired in-process research and development | |
| — | | | i 6,555 | |
Change in fair value of investments | |
| i 2,012 | | | i 205 | |
Impairment loss of long-term investments | | | — | | | i 865 | |
Changes in operating assets and liabilities: | |
| | | | | |
Accounts receivable | | | ( i 2,757) | | | ( i 773) | |
Inventories | | | ( i 3,866) | | | ( i 371) | |
Prepaid expenses and other assets | |
| ( i 238) | | | ( i 539) | |
Accounts payable | |
| ( i 1,073) | | | i 26 | |
Accrued and other current liabilities and other liabilities | |
| ( i 1,376) | | | ( i 1,770) | |
Deferred income | | | ( i 44) | | | ( i 37) | |
Net cash used in operating activities | |
| ( i 20,245) | |
| ( i 19,201) | |
| | | | | | | |
CASH FLOWS FROM INVESTING ACTIVITIES | |
|
| |
|
| |
Proceeds from disposal of property and equipment | | | i 138 | | | i 10 | |
Purchases of property, plant and equipment | | | ( i 2,186) | | | ( i 3,730) | |
Proceeds from sales of equity securities in BioInvent | | | i 1,294 | | | — | |
Receipt in advance from sales of equity investment in Juventas | | | i 16,921 | | | — | |
Cash paid to acquire equity investment in Precision Autoimmune Therapeutics Co., Ltd. | | | ( i 2,962) | | | — | |
Cash paid to acquire in-process research and development | | | — | | | ( i 6,555) | |
Cash paid to acquire convertible loan in Cleave | | | — | | | ( i 5,500) | |
Cash paid to acquire convertible loan in Black Belt Tx Limited | | | — | | | ( i 86) | |
Receipt of repayment of Black Belt convertible note | | | — | | | i 172 | |
Cash paid to acquire convertible loan in Alesta Tx | | | — | | | ( i 261) | |
Net cash provided by/(used in) investing activities | |
| i 13,205 | |
| ( i 15,950) | |
| | | | | | | |
CASH FLOWS FROM FINANCING ACTIVITIES | |
| | |
|
| |
Proceeds from bank borrowings | | | i 4,001 | | | i 709 | |
Repayment of bank borrowings | | | ( i 1,001) | | | ( i 463) | |
Repurchase of common stock | | | ( i 3,000) | | | — | |
Stock issuance costs | |
| — | | | ( i 2,019) | |
Proceeds from sale of common stock | |
| — | | | i 32,500 | |
Net cash provided by financing activities | |
| — | |
| i 30,727 | |
| | | | | | | |
Effect of exchange rate change on cash and cash equivalents | |
| ( i 2,422) | | | i 486 | |
Net decrease in cash and cash equivalents | | | ( i 9,462) | | | ( i 3,938) | |
| |
| | |
| | |
Cash, cash equivalents and restricted cash at beginning of period | | | i 38,704 | | | i 57,064 | |
Cash, cash equivalents and restricted cash at end of period | | $ | i 29,242 | | $ | i 53,126 | |
| |
|
| |
| | |
Non-cash investing and financing activities: | | | | | | | |
Purchases of property, plant and equipment in accrued and other current liabilities | | $ | i 3,111 | | $ | i 2,680 | |
Accrual for acquisition of in-process research and development | | | — | | | — | |
| | | | | | | |
Cash and cash equivalents | | $ | i 26,742 | | $ | i 53,126 | |
Restricted cash | | | i 2,500 | | | — | |
Total cash, cash equivalents and restricted cash shown in the statement of cash flows | | $ | i 29,242 | | $ | i 53,126 | |
The accompanying notes are an integral part of these consolidated financial statements.
8
CASI Pharmaceuticals, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements
i1. DESCRIPTION OF BUSINESS
CASI Pharmaceuticals, Inc. (“CASI” or the “Company”) (Nasdaq: CASI) is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company was incorporated in 1991, and in 2012, with new leadership, the Company shifted its business strategy to China and has since built an infrastructure in China that includes sales and marketing, medical affairs, regulatory and clinical development and in the foreseeable future, manufacturing. In 2014, the Company changed its name to “CASI Pharmaceuticals, Inc.” The majority of the Company’s operations and activities are now located and conducted in China. The Company is focused on acquiring, developing and commercializing products that augment its hematology/oncology therapeutic focus as well as other areas of unmet medical need. The Company is executing its plan to become a biopharmaceutical leader by launching medicines in the greater China market, leveraging its China-based regulatory, clinical and commercial competencies and its global drug development expertise.
The Company launched its first commercial product, EVOMELA® (Melphalan for Injection) in China in August 2019. In China, EVOMELA® is approved for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The other core hematology/oncology assets in the Company’s pipeline include CNCT 19, an autologous CD19 CAR-T investigative product (“CNCT19”); BI-1206, an antibody which has a novel mode-of-action, blocking the inhibitory antibody checkpoint receptor FcγRIIB to unlock anti-cancer immunity and enhance the efficacy of antibody-based immunotherapy in both hematological malignancies and solid tumors; CB-5339, a novel VCP/p97 inhibitor focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; and CID-103, a full human IgG1 anti-CD38 monoclonal antibody recognizing a unique epitope that has demonstrated encouraging preclinical efficacy and safety profile compared to other anti-CD38 monoclonal antibodies.
Liquidity and Capital Resources
Since its inception in 1991, the Company has incurred significant losses from operations and, as of September 30, 2022, had incurred an accumulated deficit of $ i 624.9 million.
The Company believes that it has sufficient resources to fund its operations at least one year beyond the date that the interim consolidated financial statements are issued. As of September 30, 2022, the Company had a balance of cash and cash equivalents and restricted cash of $ i 29.2 million, of which $ i 22.2 million was held in the financial institutions in the PRC. The Company intends to continue to exercise tight controls over operating expenditures and will continue to pursue opportunities, as required, to raise additional capital and will also actively pursue non- or less-dilutive capital raising arrangements or opportunities.
Risks and Uncertainties
Since the second quarter of 2022, due to the outbreak of Omicron and other variants of COVID-19, the lockdown in Shanghai and restrictions in other major cities in China led to limitation of access to local hospitals, which had an adverse impact on the sales of EVOMELA® for the second and the third quarters. The restrictions also adversely impacted the enrollment of patients for the CNCT19 Phase II registration studies. Recently, the pandemic gradually spread nationwide in China, and many small and medium-sized cities have been upgrading their control measures ever since the third quarter. These series of control measures are expected to adversely impact our sales activities for the remainder of 2022. Given that such COVID-19 related restrictions are beyond our control, at this stage, it is unable to assess for how long such COVID-19 related restrictions may continue in China, and the full extent to which such restrictions may directly and indirectly impact our business operations. Considering the uncertainty of the development of COVID-19 pandemic, we will continue to pay close attention on the development of the COVID-19 pandemic and dedicate resources to take any necessary measures in a timely manner to minimize the unfavorable impact on our businesses and operations.
/
9
2. License and Distribution Agreements
Acrotech License Arrangements
The Company has product rights and perpetual exclusive licenses from Acrotech Biopharma L.L.C. (“Acrotech”) to develop and commercialize its commercial product EVOMELA® (Melphalan Hydrochloride For Injection) in the greater China region (which includes Mainland China, Taiwan, Hong Kong and Macau). As well the Company had similar rights to assets ZEVALIN® (Ibritumomab Tiuxetan) and MARQIBO® (Vincristine Sulfate Liposome Injection). The exclusive licenses held by the Company were originally licensed from Spectrum Pharmaceuticals Cayman, LP Inc. (“Spectrum”), and Spectrum completed the sale of its portfolio of FDA-approved hematology/oncology products including EVOMELA® to Acrotech on March 1, 2019. On December 3, 2018, the Company received NMPA’s approval for importation, marketing and sales in China and in August 2019 the Company launched commercial sales EVOMELA® in China. The NMPA required EVOMELA® post-marketing study has been completed and the clinical study report is being finalized for regulatory submission. In May 2022, Acrotech and the Company agreed to terminate the license agreement with respect to MARQIBO® and ZEVALIN®.
China Resources Pharmaceutical Commercial Group International Trading Co., Ltd.
In March 2019, the Company entered into a i three-year exclusive distribution agreement with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd. (“CRPCGIT”) to appoint CRPCGIT on an exclusive basis as its distributor to distribute EVOMELA® in the territory of the People’s Republic of China (excluding Hong Kong, Taiwan and Macau), subject to certain terms and conditions. The Company’s internal marketing and sales team are responsible for commercial activities, including, for example, direct interaction with Key Opinion Leaders (KOL), physicians, hospital centers and the generating of sales. The agreement was renewed in March 2022 for another i two years.
Precision Autoimmune Therapeutics Co., Ltd., (previously known as Beijing Tianshi Tongda Pharmaceuticals Technology Co., Ltd)
In May 2022, the Company entered into a Sublicense Agreement (the “Sublicense Agreement”) with Precision Autoimmune Therapeutics Co., Ltd. (“PAT”), a company established under the laws of China, pursuant to which the Company granted PAT an exclusive (subject to the Commercialization and Co-Marketing rights), perpetual, worldwide license, with the right to freely grant further sublicenses subject to terms and conditions in the Sublicense Agreement, for the investigational anti-CD38 monoclonal antibody TSK011010 licensed and controlled by the Company from Black Belt Therapeutics Limited, in the treatment, prevention and diagnosis of autoimmune diseases, conditions and disorders in humans.
Pursuant to the Sublicense Agreement, PAT will make an upfront payment of $ i 10,000,000 equivalent in i two equal instalments upon completion of its first and second financing, respectively, plus potential future payments of development and sales milestones and royalties to the Company.
Also in May 2022, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”) entered into an agreement for the investment in PAT in the amount of RMB i 20.0 million (approximately $ i 3.0 million) in cash during PAT’s first equity financing (see Note 5).
Juventas Biotechnology (Tianjin) Co., Ltd. (“Juventas”)
In June 2019, the Company entered into a license agreement for exclusive worldwide license to commercialize an autologous anti-CD19 T-cell therapy product (CNCT19) from Juventas (the “Exclusive License Agreement”). Juventas is a China-based company engaged in cell therapy. The terms of the agreement include RMB i 70 million ($ i 10 million) of milestone payments upon the registration of Phase II clinical trial of CNCT19 and sales royalty payments. The milestone was met during the third quarter of 2020, the Company paid the milestone payment of RMB i 70 million to Juventas in September 2020, and recognized it as acquired in-process research and development expenses in the consolidated statement of operations and comprehensive loss in 2020.
In September 2020, Juventas and its shareholders (including CASI Biopharmaceuticals (Wuxi) Co., Ltd (“CASI Biopharmaceuticals”), a subsidiary of the Company, ) agreed to certain terms and conditions required by a new third-party investor to facilitate the Series B financing of Juventas, pursuant to which the Company agreed to amend and supplement the original licensing agreement (the "Supplementary Agreement") by agreeing to pay Juventas certain percentage of net profits generated from commercial
/10
sales of CNCT19 in addition to the royalty fee payment calculated as a percentage of net sales. The Supplementary Agreement also specifies a minimum annual target net profit to be distributed to Juventas and certain other terms and obligations. In return, the Company obtained additional equity interests in Juventas.
Under the Supplementary Agreement, Juventas and the Company will jointly market CNCT19, including, but not limited to, establishing medical teams, developing medical strategies, conducting post-marketing clinical studies, establishing Standardized Cell Therapy Centers, establishing and training providers with respect to cell therapy, testing for cell therapy, and monitoring quality controls (cell collection and transfusion, etc.), and patient management (adverse reactions treatment, patients’ follow-up visits, and establishment of a database). The Company also will reimburse Juventas for a portion of Juventas’ marketing expenses as reviewed and approved by a joint commercial committee to be constituted. The Company will continue to be responsible for recruiting and establishing a sales team to commercialize CNCT19.
In September 2022, CASI Biopharmaceuticals entered into an Equity Transfer Agreement to transfer its equity interest in Juventas in the amount of RMB i 240.9 million (approximately $ i 33.8 million) to a limited partnership enterprise (see Note 5). The Exclusive License Agreement is still effective after this equity transfer.
BioInvent International AB
In October 2020, the Company entered into an exclusive licensing agreement with BioInvent International AB (“BioInvent”) for the development and commercialization of novel anti-FcγRIIB antibody, BI-1206, in Mainland China, Taiwan, Hong Kong and Macau. BioInvent is a biotechnology company focused on the discovery and development of first-in-class immune-modulatory antibodies for cancer immunotherapy. BI-1206 is being investigated in a Phase 1/2 trial, in combination with anti-PD1 therapy Keytruda® (pembrolizumab), in patients with solid tumors, and in a Phase 1/2a trial in combination with MabThera® (rituximab) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). The CASI Clinical Trial Application (CTA) was approved by China National Medical Products Administration (NMPA) in December 2021 and ethics committee approvals have been received in January of 2022. The Company obtained approval from Human Genetic Resources Administration of China (“HGRAC”) in April 2022. The Company is planning a Phase 1 study of BI-1206 in combination with rituximab with a single agent BI-1206 run in phase in patients with NHL (mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma) to assess PK, safety and tolerability, select the Recommended Phase 2 Dose and assess early signs of clinical efficacy as part of its development program for BI-1206 in China. The study received regulatory approval from the China Center for Drug Evaluation (“CDE”) in the second quarter of 2022, and the first-patient dosing was achieved in the third quarter of 2022.
Under the terms of the agreement, BioInvent and CASI will develop BI-1206 in both hematological malignancies and solid tumors, with CASI responsible for commercialization in China and associated markets. CASI made a $ i 5.9 million upfront payment in November 2020 to BioInvent and will pay up to $ i 83 million in development and commercial milestone payments plus tiered royalties in the high-single to mid-double-digit range on net sales of BI-1206. Because BI-1206 underlying the acquired rights has not reached technological feasibility and has no alternative future uses, the Company expensed $ i 5.9 million as acquired in-process research and development in 2020.
Black Belt Therapeutics Limited
In April 2019, the Company entered into a license agreement with Black Belt Therapeutics Limited (“Black Belt”) for exclusive worldwide rights to CID-103, an investigational anti-CD38 monoclonal antibody (Mab) (formerly known as TSK011010). The Company expects that its clinical materials and commercial inventory will be supplied by one or more contract manufacturers with whom the Company has contracted with. Under the terms of the agreement, CASI obtained global rights to CID-103 for an upfront payment of i 5 million euros ($ i 5.7 million) and would pay up to $ i 46.3 million in development milestone payments and certain royalties based on sales milestones. In June 2021, the Company achieved the First-Patient-In (FPI) in the Phase 1 dose escalation and expansion study of CID-103, and made $ i 750,000 milestone payment in June 2021 and € i 250,000 ($ i 305,000) payment in August 2021 under the terms of the agreement. Because CID-103 underlying the acquired rights has not yet reached technological feasibility and has no alternative uses, the Company expensed i 5 million euros and $ i 1.1 million as acquired in-process research and development, respectively, in 2019 and 2021. As mentioned above, in May 2022, the Company entered into the Sublicense Agreement to grant PAT an exclusive, perpetual, worldwide license, for the investigational anti-CD38 monoclonal antibody TSK011010.
11
Cleave Therapeutics, Inc.
In March 2021, the Company entered into an exclusive license with Cleave Therapeutics, Inc. (“Cleave”) for the development and commercialization of CB-5339, an oral novel VCP/p97 inhibitor, in both hematological malignancies and solid tumors, in Mainland China, Hong Kong, Macau and Taiwan. Cleave is a clinical-stage biopharmaceutical company focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response and other cellular stress pathways for therapeutic use in the treatment of patients with cancer. Cleave and the Company will develop CB-5339 in both hematological malignancies and solid tumors, with CASI responsible for development and commercialization in China and associated markets. The Company paid a $ i 5.5 million upfront payment to Cleave in 2021 and will pay up to $ i 74 million in development and commercial milestone payments plus tiered royalties in the high-single to mid-double-digit range on net sales of CB-5339.
CB-5339 is being evaluated by Cleave in a Phase 1 clinical trial in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Because CB-5339 has not yet reached technological feasibility and has no alternative future uses, the Company expensed the $ i 5.5 million upfront payment as acquired in-process research and development in 2021.
Pharmathen Global BV
On October 29, 2019, the Company entered into an exclusive distribution agreement with Pharmathen Global BV ("Pharmathen") for the development and distribution of octreotide long acting injectable (Octreotide LAI) microsphere in China. Octreotide LAI formulations, which are approved in various European countries, are considered a standard of care for the treatment of acromegaly and the control of symptoms associated with certain neuroendocrine tumors.
The terms of the agreement include an upfront payment of i 1 million euros which was paid by the Company in 2019, and up to i 2 million euros of additional milestone payments, of which i 1.5 million euros ($ i 1.7 million) was paid by the Company with achievements of certain milestones and was expensed as acquired in-process research and development in 2020. CASI is responsible for the development, import drug registration, product approval and commercialization in China. CASI has a 10-year non-royalty exclusive distribution period after the product launch at an agreed supply costs for the first i three years.
Riemser Pharma GmbH
In August 2019, the Company entered into a distribution agreement in China with Riemser Pharma GmbH (“Riemser”) to a novel formulation of thiotepa, a chemotherapeutic agent, which has multiple potential indications including use as a conditioning treatment for use prior to allogenic hematopoietic stem cell transplantation. Thiotepa has a long history of established use in the hematology/oncology setting. Pursuant to the distribution agreement, CASI obtained the exclusive distribution right of the products in China, and Riemser will be responsible for manufacturing and supplying CASI with clinical materials and commercial inventory. The Company is applying for NADA registration and, subject to regulatory and marketing approvals, the Company intends to advance and commercialize this product in China. In January 2020, Riemser was acquired by Esteve Healthcare, S.L. (“ESTEVE”), an international pharmaceutical company headquartered in Barcelona, Spain. There is i no contingent milestone payment due to Riemser under the agreement.
i3. Summary of Significant Accounting Policies
iBasis of Presentation
The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
iUse of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company's significant accounting estimates relate to recoverability of operating lease right-of-use assets, intangible assets and long-term investments, net realizable value and obsolescence allowance for inventories, deferred tax assets and valuation allowance, allowance for doubtful accounts, stock-based arrangements and fair value of investments. Management bases its estimates on historical experience and on
/12
various other assumptions that it believes are reasonable under the circumstances. Actual results may differ from those estimates, and such differences may be material to the consolidated financial statements.
iRecent Accounting Pronouncements
In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. This update requires certain annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. This update is effective for annual periods beginning after December 15, 2021, and early application is permitted. This guidance should be applied either prospectively to all transactions that are reflected in financial statements at the date of initial application and new transactions that are entered into after the date of initial application or retrospectively to those transactions. The Company does not expect the impact of this guidance to have a material impact on the Company’s consolidated financial statements.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments — Credit Losses (Topic 326) (“ASU 2016-13”) and subsequent amendments to the initial guidance including ASU No. 2018-19, ASU No. 2019-04, and ASU No. 2019-05 (collectively, “Topic 326”). Topic 326 requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. This standard is effective for public business entities, excluding entities eligible to be smaller reporting companies for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For all other entities, this standard is effective for annual and interim periods beginning after December 15, 2022 and early adoption is permitted for annual and interim periods beginning after December 15, 2018. As a smaller reporting company, the Company expects to adopt this standard in fiscal year 2023. The Company is currently assessing the impact that the adoption of this ASU will have on the consolidated financial statements.
i4.Revenue Related Information
The Company’s revenue is primarily consisted of sales of EVOMELA ®. As of September 30, 2022, the Company did not incur, and therefore did not defer, any material costs to obtain or fulfill contracts. The Company did not have any contract assets or contract liabilities as of September 30, 2022 and December 31, 2021. There was no product exchange during the periods ended September 30, 2022 and 2021.
i5. Investment in Equity Securities, at Fair Value and Long-term Investments
Investment in Equity Securities, at Fair Value
The following table summarizes the Company’s investment in equity securities at fair value as of September 30, 2022 and December 31, 2021, respectively:
i
| | | | | | | | | | | |
| | | | | | | Gross | | | | |
(In thousands) | | | | | | | unrealized | | Aggregate fair | ||
| Classification |
| Cost |
| gains /(losses) |
| value | ||||
MaxCyte - equity interest |
| Investment | | $ | — | | $ | i 2,453 | | $ | i 2,453 |
BioInvent - equity interest |
| Investment | | $ | i 4,337 | | $ | ( i 481) | | $ | i 3,856 |
Total | | | | | | | | | | $ | i 6,309 |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | Gross | | | | |
(In thousands) | | | | | | | unrealized | | Aggregate fair | ||
| Classification |
| Cost |
| gains |
| value | ||||
MaxCyte - equity interest |
| Investment | | $ | — | | $ | i 3,866 | | $ | i 3,866 |
BioInvent - equity interest |
| Investment | | $ | i 5,661 | | $ | i 341 | | $ | i 6,002 |
Total | | | | | | | | | | $ | i 9,868 |
In the second quarter of 2022, the Company sold i 275,000 ordinary shares of BioInvent for $ i 1.3 million. The Company recognized gains of $ i 131,000 in consolidated statements of operations and comprehensive loss.
/13
For the three and nine months ended September 30, 2022, the Company recognized unrealized gains of $ i 0.6 million and unrealized losses $ i 2.5 million, respectively, on the Company’s equity investments. For the three and nine months ended September 30, 2021, the Company recognized unrealized losses of $ i 3.7 million and $ i 0.3 million, respectively, on the Company’s equity investments. Unrealized gains (losses) on the Company’s equity investments are recognized as change in fair value of investment in the consolidated statements of operations and comprehensive loss.
Long-term Investments
iLong-term investments as of September 30, 2022 and December 31, 2021 consisted of the following:
| | | | | | | | | | | | | | | |
| | | | | | | | Gross | | Foreign | | | | ||
| | | | | Gross | | unrealized | | currency | | | | |||
| | | | unrealized | | losses (including | | translation | | Aggregate | |||||
(In thousands) |
| Cost |
| gains |
| impairment) |
| adjustment |
| fair value | |||||
Available-for-sale debt securities: |
| |
|
| |
|
| |
|
| |
| | | |
Alesta Therapeutics B.V. - convertible loan | | $ | i 261 | | $ | i 15 | | $ | — | | $ | — | | $ | i 276 |
Securities measured at fair value: | | | | | | | | | | | | | | | |
BioInvent International AB - warrants | | | i 656 | | | — | | | ( i 194) | | | — | | | i 462 |
Cleave Therapeutics, Inc. - convertible loan | | | i 5,500 | | | i 458 | | | — | | | — | | | i 5,958 |
Equity securities without readily determinable fair value: | |
|
| |
|
| |
|
| |
|
| |
| |
Alesta Therapeutics B.V. - equity interests | |
| i 2,250 | |
| — | |
| ( i 865) | |
| — | |
| i 1,385 |
Juventas Biotechnology (Tianjin) Co., Ltd. - equity interests | |
| i 23,500 | |
| i 6,958 | |
| — | |
| ( i 1,569) | |
| i 28,889 |
Juventas Biotechnology (Tianjin) Co., Ltd. - put option | |
| i 491 | |
| — | |
| ( i 521) | |
| i 30 | |
| — |
Prepayment for investment: | | | | | | | | | | | | | | | |
Precision Autoimmune Therapeutics Co., Ltd - equity interests | | | i 2,962 | | | — | | | — | | | ( i 152) | | | i 2,810 |
Total | | $ | i 35,620 | | $ | i 7,431 | | $ | ( i 1,580) | | $ | ( i 1,691) | | $ | i 39,780 |
| | | | | | | | | | | | | | | |
| | | | | | | | Gross | | Foreign | | | | ||
| | | | | Gross | | unrealized | | currency | | | | |||
| | | | unrealized | | losses (including | | translation | | Aggregate | |||||
(In thousands) |
| Cost |
| gains |
| impairment) |
| adjustment |
| fair value | |||||
Available-for-sale debt securities: |
| |
|
| |
|
| |
|
| |
| | | |
Alesta Therapeutics B.V. - convertible loan | | $ | i 261 | | $ | i 7 | | $ | — | | $ | — | | $ | i 268 |
Securities measured at fair value: | | | | | | | | | | | | | | | |
BioInvent International AB - warrants | | | i 656 | | | — | | | ( i 65) | | | — | | | i 591 |
Cleave Therapeutics, Inc. - convertible loan | | | i 5,500 | | | i 76 | | | — | | | — | | | i 5,576 |
Equity securities without readily determinable fair value: | |
| | |
| | |
| | |
| | |
| |
Alesta Therapeutics B.V. - equity interests | |
| i 2,250 | |
| — | |
| ( i 865) | |
| — | |
| i 1,385 |
Juventas Biotechnology (Tianjin) Co., Ltd. - equity interests | |
| i 23,500 | |
| i 6,958 | |
| — | |
| i 1,850 | |
| i 32,308 |
Juventas Biotechnology (Tianjin) Co., Ltd. - put option | |
| i 491 | |
| — | |
| ( i 521) | |
| i 30 | |
| — |
Total | | $ | i 32,658 | | $ | i 7,041 | | $ | ( i 1,451) | | $ | i 1,880 | | $ | i 40,128 |
Investment in Precision Autoimmune Therapeutics Co., Ltd., (“PAT”)
In May 2022, CASI China entered into an agreement for the investment in PAT in the amount of RMB i 20.0 million (approximately $ i 3.0 million) in cash during PAT’s first equity financing. CASI China has paid all the consideration in June 2022. Upon consummation of such equity financing, CASI China will hold i 15% equity interests of PAT and will hold one third of the board seats.
14
As of September 30, 2022, the transaction had not been consummated as the consideration from other investors has not been paid in full.
Sales of Investment in Juventas Biotechnology (Tianjin) Co., Ltd.
In September 2022, CASI Biopharmaceuticals entered into an equity transfer agreement (the “Equity Transfer Agreement”) with Shenzhen Jiadao Gongcheng Equity Investment Fund (Limited Partnership) (“Jiadao Gongcheng”), a third party limited partnership enterprise incorporated under the laws of China, pursuant to which CASI Biopharmaceuticals agreed to transfer to Jiadao Gongcheng all of its equity interest in Juventas in the amount of RMB i 240.9 million (approximately $ i 33.8 million). Pursuant to the Equity Transfer Agreement, CASI Biopharmaceuticals will transfer all of its rights and obligations to Jiadao Gongcheng, and Jiadao Gongcheng would make payment in two equal installments, with the first installment paid after signing the Equity Transfer Agreement and the second installment paid shortly after the completion of the registration with competent government authorities. As of September 30, 2022, CASI Biopharmaceuticals received the first installment of RMB i 120.4 million (approximately $ i 16.9 million) as advance. The transaction had not been consummated as the registration with competent governmental authorities of the transaction was still in process.
i6. Inventories
The Company’s inventories consist of finished goods amounted to $ i 5.8 million and $ i 1.9 million, as of September 30, 2022 and December 31, 2021, respectively. i i i i No / / / write down to the carrying amount of inventory have been recorded in the three and nine months ended September 30, 2022 and 2021.
/
i7.Property, Plant and Equipment
Property, plant and equipment consist of the following:
i
| | | | | | |
(In thousands) | | September 30, | | |||
|
| 2022 |
| 2021 | ||
Furniture and equipment | | $ | i 1,169 | | $ | i 1,728 |
Leasehold improvements | |
| i 6,944 | |
| i 1,133 |
Construction in progress | | | i 7,358 | | | i 12,095 |
Total property, plant and equipment, gross | |
| i 15,471 | |
| i 14,956 |
Accumulated depreciation and amortization | | | ( i 1,604) | | | ( i 1,817) |
Impairment of property, plant and equipment | |
| — | |
| ( i 427) |
| | $ | i 13,867 | | $ | i 12,712 |
In the third quarter of 2022, CASI Wuxi obtained the Certificate for Pharmaceutical Distribution, and then transferred certain assets related to the manufacturing facility in Wuxi from construction in process to leasehold improvements and furniture and equipment and started to depreciate those assets.
/
i8. Leases
Right of use (“ROU”) assets and liabilities for operating leases are recognized at commencement date based on the present value of lease payments over the lease term. Rent expense is recognized on a straight-line basis over the lease term.
Liabilities for operating lease are included in accrued and other current liabilities and other liabilities (noncurrent) in the consolidated balance sheets as of September 30, 2022 and December 31, 2021.
In November 2019, CASI Wuxi entered into a i fifty-year lease agreement for the right to use state-owned land in China for the construction of a manufacturing facility. The land parcel is i 74,028.40 square meters. The Company classifies this lease as an operating
/15
lease. The Company prepaid all of the lease payments for the land use right in 2019 in the amount of RMB i 45 million (equivalent to $ i 6.5 million).
Rent expense for the nine months ended September 30, 2022 and 2021 was $ i 1.0 million and $ i 1.2 million, respectively. There were i i no / variable lease costs or sublease income for leased assets for the nine months ended September 30, 2022 and 2021.
Right of use assets and liabilities as of September 30, 2022 and December 31, 2021 on the condensed consolidated balance sheets were as follows:
i
| | | | | | | |
|
| September 30, | | December 31, |
| ||
(In thousands) |
| 2022 |
| 2021 | | ||
Right of use assets | | $ | i 7,666 | | $ | i 9,107 | |
| | | | | | | |
Accrued and other current liabilities | | $ | i 922 | | $ | i 1,061 | |
Other liabilities | |
| i 634 | |
| i 1,105 | |
Total lease liabilities | | $ | i 1,556 | | $ | i 2,166 | |
Supplemental cash flow information related to leases was as follows:
i
| | | | | | |
|
| Nine Months Ended September 30, | ||||
(In thousands) | | 2022 | | 2021 | ||
Cash paid for amounts included in the measurement of lease liabilities: |
| |
| | |
|
Operating cash flows | | $ | i 859 | | $ | i 1,087 |
| | | | | | |
Right of use assets obtained in exchange for lease obligations: | | $ | i 421 | | $ | i 1,661 |
All of the Company’s existing leases as of September 30, 2022 and December 31, 2021 were classified as operating leases. As of September 30, 2022 and December 31, 2021, the Company had i seven and i eight, respectively, material operating leases for land and facilities with remaining terms expiring from 2023 through 2069 and a weighted average remaining lease term of i 37.92 years and i 36.47 years, respectively. The Company has fair value renewal options for many of the Company’s existing leases, none of which are considered reasonably certain of being exercised or included in the minimum lease term. Weighted average discount rates used in the calculation of the lease liability as of September 30, 2022 and December 31, 2021 were i 3.53% and i 3.56%, respectively. The discount rates reflect the estimated incremental borrowing rate, which includes an assessment of the credit rating to determine the rate that the Company would have to pay to borrow, on a collateralized basis for a similar term, an amount equal to the lease payments in a similar economic environment.
A maturity analysis representing the future undiscounted cash flow of the Company’s operating leases liabilities as of September 30, 2022 is as follows:
i
| | | |
(In thousands) |
|
| |
2022 (remaining three months) | | $ | i 266 |
2023 |
| | i 871 |
2024 |
| | i 456 |
Thereafter |
| | i 12 |
Total |
| | i 1,605 |
Discount factor |
| | ( i 49) |
Lease liability |
| | i 1,556 |
Amounts due within 12 months |
| | i 922 |
Non-current lease liability | | $ | i 634 |
16
9.Accrued and Other Current Liabilities, and Other Liabilities
i
| | | | | | |
| | September 30, | | December 31, | ||
(In thousands) |
| 2022 |
| 2021 | ||
Accrued and other current liabilities: | | | | | | |
Receipt in advance for sale of an investment (1) | | | i 16,921 | | | — |
Payables related to property and equipment | |
| i 3,111 | | | i 3,288 |
Payroll and welfare payable | | $ | i 2,037 |
| $ | i 3,336 |
Lease liabilities-current | |
| i 922 | | | i 1,061 |
Value-added tax and other tax payable | | | i 255 | | | i 639 |
Deferred income-current | | | i 54 | | | i 60 |
Other | | | i 351 |
| | i 13 |
| | $ | i 23,651 | | $ | i 8,397 |
| | | | | | |
Other Liabilities | | | | | | |
Profit-sharing liability to Juventas | | $ | i 11,821 | | $ | i 13,220 |
Lease liabilities-noncurrent | | | i 634 | | | i 1,105 |
| | $ | i 12,455 | | $ | i 14,325 |
Note (1): The receipt in advance for sale of an investment represents the first installment received for sale of Juventas (see Note 5).
/
i10. Bank Borrowings
In May 2022, the Company entered into a Business Loan Agreement (together with related security agreements and promissory note, the “Agreement”) with East West Bank (“EWB”). Under the Agreement, EWB made available to the Company a revolving line of credit up to a maximum of $ i 10.0 million. The Agreement will mature on December 31, 2022, unless extended to April 30, 2024 subject to certain conditions as defined in the Agreement. In general, amounts borrowed under the Agreement are secured by a lien on the Company’s assets, including first priority security interest in accounts receivable and inventory and pledge of available-for-sale securities. As of September 30, 2022, the outstanding principal balance under this agreement was $ i 3.0 million.
In June 2022, the Company’s subsidiary, CASI China entered into a Loan Agreement with China International Trust and Investment Corporation Bank (“CITIC Bank”). Under the Loan Agreement, CITIC Bank made available to CASI China a guaranteed line of credit up to a maximum of RMB i 20.0 million (approximately $ i 3.0 million). The Loan Agreement will mature on June 13, 2023. The joint and several liability guarantee was provided by Beijing Shouchuang Financing Guarantee Co. Ltd. concurrently with the Loan Agreement. The loan was secured by a pledge of the land use right held by CASI Wuxi, one of the Company’s subsidiaries. Interest accrues on the principal amounts of the loans outstanding at a fixed annual rate of i 3.98% and payable monthly. In the second quarter of 2022, CASI China made a drawdown under the loan amounted to RMB i 6.7 million ($ i 1.0 million) and repaid all the outstanding principal balance and interest in the third quarter of 2022. The Loan Agreement was terminated in July 2022 and the land use right was released from the pledge in September 2022.
17
11. Redeemable Noncontrolling Interest
Changes in redeemable noncontrolling interest during the nine month periods ended September 30, 2022 and 2021 are as follows:
i
| | | | | | | |
| | Nine Months Ended September 30, | | ||||
(In thousands) | | 2022 | | 2021 | | ||
Balance at beginning of period | | $ | i 23,457 |
| $ | i 22,033 | |
Share of CASI Wuxi net loss | |
| ( i 1,703) | | | ( i 980) | |
Accretion of redeemable noncontrolling interest | |
| i 2,264 | | | i 1,586 | |
Foreign currency translation adjustment | | | ( i 2,515) | | | i 268 | |
Balance at end of period | | $ | i 21,503 |
| $ | i 22,907 | |
/
i12. Stockholders’ Equity
Reverse Stock Split
On June 1, 2022, the Company effectuated a reverse stock split of the Company’s Common Stock (the “Reverse Stock Split”) pursuant to an amendment to its Amended and Restated Certificate of Incorporation filed on May 26, 2022. Trading of the Common Stock on a reverse stock split-adjusted basis began at the opening of trading on the Nasdaq Capital Market on June 2, 2022. After the reverse stock split, each ten ( i 10) shares of Common Stock issued and outstanding was combined into one (1) validly issued, fully paid and non-assessable share of Common Stock. The par value per share of the Common Stock remains the same. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to a fractional share of Common Stock were instead entitled to receive a proportional cash payment. The Reverse Stock Split did not reduce the total number of shares of Common Stock that the Company is authorized to issue, which remains i 250,000,000 shares. In addition, proportionate adjustments was made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options and warrants to purchase shares of Common Stock and the number of shares of Common Stock reserved for issuance pursuant to the Company’s equity incentive plans. Unless otherwise indicated, all share numbers in this report have been adjusted to reflect the Reverse Stock Split. Net loss per share was adjusted retrospectively.
Stock Repurchase Program
On December 15, 2021, the board of directors of the Company approved a stock repurchase program for the repurchase of up to $ i 10 million of the Company’s Common Stock (and no more than i 12,500,000 shares of the Company’s Common Stock, not adjusted to reflect the Reverse Stock Split) through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934 and through trading plans established pursuant to Rule 10b5-1 of the Securities Exchange Act from time to time. The Company established a Rule 10b5-1 trading plan to carry out the stock repurchase, which was terminated on March 31, 2022, and as of the termination of the plan, the Company has repurchased i 3,734,992 shares of Common Stock (among which i 2,541,245 shares of Common Stock were retired, not adjusted to reflect the Reverse Stock Split) amounted to $ i 3.0 million.
Stock Purchase Warrants
In history, the Company issued shares of its common stock with accompanying warrants to certain institutional investors, accredited investors and existing stockholders.
As of September 30, 2022, the outstanding and exercisable number of warrants was i 617,277 with weighted average exercise price of $ i 36.9. All outstanding warrants are equity classified.
/
i13. Net Loss Per Share
Net loss per share (basic and diluted) was computed by dividing net loss attributable to common stockholders, considering the accretions to redemption value of the redeemable noncontrolling interest, by the weighted average number of shares of common stock outstanding. As of September 30, 2022 and December 31, 2021, outstanding stock options totaling i 3,415,729 and i 3,324,368,
/18
respectively, and outstanding warrants both totaling i i 617,277 / , were anti-dilutive, and therefore, were not included in the computation of weighted average shares used in computing diluted loss per share. Pursuant to the reverse stock split, net loss per share was adjusted retrospectively.
The following table sets forth the basic and diluted net loss per share computation and provides a reconciliation of the numerator and denominator for the periods presented:
i
| | | | | | | | | | | | | |
| | Three Months Ended September 30, |
| Nine Months Ended September 30, |
| ||||||||
(In thousands, except share and per share data) | | 2022 | | 2021 |
| 2022 | | 2021 |
| ||||
Numerator: |
| |
|
| | |
| |
|
| | | |
Net loss attributable to CASI Pharmaceuticals, Inc. | | $ | ( i 5,201) | | | ( i 10,224) | | $ | ( i 21,477) | | $ | ( i 31,053) | |
Denominator: | |
| | | | | |
| | | | | |
Weighted average number of common stock | |
| i 13,606,130 | | | i 13,979,636 | |
| i 13,668,553 | |
| i 13,486,024 | |
Denominator for basic and diluted net loss per share calculation | |
| i 13,606,130 | | | i 13,979,636 | |
| i 13,668,553 | |
| i 13,486,024 | |
Net loss per share | |
|
| | | | |
|
| | | | |
— Basic and diluted | | $ | ( i 0.38) | | $ | ( i 0.73) | | $ | ( i 1.57) | | $ | ( i 2.30) | |
i14. Stock-Based Compensation
The Company has adopted various stock compensation plans for executive, scientific and administrative personnel of the Company, as well as outside directors and consultants.
The stock-based compensation expenses are recorded as components of research and development expense, sales and marketing expense, and general and administrative expense, as follows:
i
| | | | | | | |
| | Nine Months Ended September 30, | | ||||
(In thousands) |
| 2022 |
| 2021 |
| ||
Research and development | | $ | i 504 | | $ | i 251 | |
Sales and Marketing | | | i 183 | | | i 212 | |
General and administrative | |
| i 4,904 | |
| i 4,596 | |
Stock-based compensation expense | | $ | i 5,591 | | $ | i 5,059 | |
/
i15. Income Taxes
At December 31, 2021, the Company had a $ i 1.4 million unrecognized tax benefit. The Company recorded a full valuation allowance on the deferred tax asset after offsetting unrecognized tax benefit recognized in the consolidated financial statements as of December 31, 2021.
During the nine months ended September 30, 2022, there were i no material changes to the measurement of unrecognized tax benefits in various tax jurisdictions.
/
i16. Fair Value Measurements
Financial instruments of the Company primarily consist of cash and cash equivalents, investment in equity securities, accounts receivable, long-term investments, accounts payable, accrued liabilities, notes payable and bank borrowings. As of September 30, 2022 and December 31, 2021, the carrying amount of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, notes payable and bank borrowings were carried at cost which approximates their fair values due to the short-term nature of the instruments.
19
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the hierarchy.
The Company has equity investments in the common stock of two publicly traded companies. The Company’s investments in these equity securities are carried at their estimated fair value, with changes in fair value reported in the consolidated statement of operations and comprehensive loss each reporting period. The fair value of the common stock is based on quoted market price for the investees’ common stock, a Level 1 input.
The Company has an equity investment in the warrants of a publicly traded company. The Company’s investment is carried at its estimated fair value, with changes in fair value reported in the consolidated statement of operations and comprehensive loss each reporting period. The fair value of the warrants was measured using observable market-based inputs other than quoted prices in active markets for identical assets, level 2 inputs. The Company uses the Black-Scholes-Merton valuation model to estimate the fair value of warrants. Option valuation models, including Black-Scholes-Merton, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the fair value determination of a warrant.
The Company has an investment in the convertible debt of Alesta Therapeutics B.V.. The Company’s investment is carried at its estimated fair value, with changes in fair value reported in the consolidated statement of operations and comprehensive loss each reporting period using Level 3 input.
The Company has an investment in the convertible debt of Cleave. The Company’s investment is carried at its estimated fair value, with changes in fair value reported in the consolidated statement of operations and comprehensive loss each reporting period using Level 3 input. The unpaid balance for this convertible debt amounted to $ i 5.8 million and $ i 5.6 million as of September 30, 2022 and December 31, 2021, respectively.
The following tables present the Company’s financial assets accounted for at fair value on a recurring basis as of September 30, 2022 and December 31, 2021, by level within the fair value hierarchy:
i
| | | | | | | | | | | | |
(In thousands) | | Fair Value at | | | | | | | | | | |
Description |
|
| Level 1 |
| Level 2 |
| Level 3 | |||||
Investments classified as Current and non-Current Assets | | | | | | | | | | | | |
Investments in common stock | | $ | i 6,309 | | $ | i 6,309 | | $ | i — | | $ | i — |
Investment in warrants - Designated as investment measured at FVTPL | | $ | i 462 | | $ | i — | | $ | i 462 | | $ | i — |
Investment in convertible loan - AFS | | $ | i 276 | | $ | i — | | $ | i — | | $ | i 276 |
Investment in convertible loan - Designated as investment measured at FVTPL | | $ | i 5,958 | | $ | i — | | $ | i — | | $ | i 5,958 |
| | | | | | | | | | | | |
| | Quantitative Information about Level 3 Fair Value Measurements | ||||||||||
| | Fair Value at | | Valuation | | Unobservable | | | | |||
Description |
|
| Techniques |
| Input |
| Average/Median | |||||
Investment in convertible loan - Designated as investment measured at FVTPL | | $ | i 5,958 | | | Discounted cash flow | | | Discount rate | | | i 20%/ i 20% |
/20
| | | | | | | | | | | | |
(In thousands) |
| Fair Value at | | | | | | | | | | |
Description |
|
| Level 1 |
| Level 2 |
| Level 3 | |||||
Investments classified as Current and non-Current Assets | | | | | | | | | | | | |
Investments in common stock | | $ | i 9,868 | | $ | i 9,868 | | $ | i — | | $ | i — |
Investment in warrants - Designated as investment measured at FVTPL | | $ | i 591 | | $ | i — | | $ | i 591 | | $ | i — |
Investment in convertible loan - AFS | | $ | i 268 | | $ | i — | | $ | i — | | $ | i 268 |
Investment in convertible loan - Designated as investment measured at FVTPL | | $ | i 5,576 | | $ | i — | | $ | i — | | $ | i 5,576 |
| | | | | | | | | | | | |
| | Quantitative Information about Level 3 Fair Value Measurements | ||||||||||
| | Fair Value at | | Valuation | | Unobservable | | | | |||
Description |
|
| Techniques |
| Input |
| Average/Median | |||||
Investment in convertible loan - Designated as investment measured at FVTPL | | $ | i 5,576 | | | Discounted cash flow | | | Discount rate | | | i 20%/ i 20% |
Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis
The Company measures equity investments without readily determinable fair values at its cost, minus impairment, if any, plus or minus changes resulting from observable transactions of identical or similar securities of the same issuer.
Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
The Company had i no non-financial assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2022.
Non-Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis
The Company had i no non-financial assets and liabilities that are measured at fair value on a non-recurring basis as of September 30, 2022.
i17. Related Party Transactions
Transactions with Juventas.
On July 1, 2019 the Company entered into a i one-year equipment lease with Juventas, which is classified as an operating lease. Transactions with Juventas are considered to be related party transactions as the Company’s Chairman and CEO is the chairman and one of the founding shareholders of Juventas. The lease was renewed for another year in July 2020 and in June 2021. In June 2022, the Company and Juventas entered into a lab equipment transfer contract, pursuant to which the previous leasing agreement was terminated and the Company transferred the equipment to Juventas. Total consideration for the transfer was RMB i 900,000 ($ i 138,000) in cash.
/ i18. Commitments and Contingencies
In conjunction with the Cleave agreement entered into during 2021 (see Note 2), the Company is responsible for certain milestone and royalty payments. As of September 30, 2022, i no milestones had been achieved.
In conjunction with the BioInvent agreement entered into during 2020 (see Note 2), the Company is responsible for certain milestone and royalty payments. As of September 30, 2022, i no milestones had been achieved.
In conjunction with the Black Belt agreement entered into during 2019 (see Note 2), the Company is responsible for certain milestone and royalty payments. In June 2021, the Company achieved the First-Patient-In (FPI) in the Phase 1 dose escalation and expansion study of CID-103, and made $ i 750,000 milestone payment in June 2021 and i 250,000 euros ($ i 305,000) in August 2021. As of September 30, 2022, i no other milestones had been achieved.
/21
In conjunction with the Pharmathen agreement entered into during 2019 (see Note 2), the Company is responsible for i one remaining milestone payment. As of September 30, 2022, the remaining milestone had not been achieved.
To develop a GMP manufacturing facility, in November 2019, CASI Wuxi entered into a lease agreement of a state-owned land and committed to invest in land use right and property, plant and equipment for RMB i 1 billion (equivalent to $ i 143 million) by August 2022. In February 2022, the Company has reached an alignment with the Wuxi local government that the original three-year investment plan will be extended with details regarding the plan under negotiation, and most of the construction work related to the Wuxi land has not started yet. In 2020, CASI Wuxi entered into a lease agreement with local government for a manufactory building next to the leased land and a series of contracts for the construction and equipment. The total contract amount entered into for this manufacturing facility is approximately RMB i 174.5 million (approximately $ i 24.5 million), and the commitment under these contracts was RMB i 59.2 million (approximately $ i 8.3 million) as of September 30, 2022.
The Company is subject in the normal course of business to various legal proceedings in which claims for monetary or other damages may be asserted. Management does not believe such legal proceedings, unless otherwise disclosed herein, are material.
i19. Subsequent Event
In October 2022, pursuant to the Equity Transfer Agreement entered into between CASI Biopharmaceuticals and Jiadao Gongcheng for the sales of the equity interest in Juventas, the registration with competent governmental authorities of the transaction has been completed.
In October 2022, the Company sold all the ordinary shares of MaxCyte for $ i 2.4 million.
/
22
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
OVERVIEW
CASI Pharmaceuticals, Inc. (“CASI” or the “Company”, or “we” or “our”) (Nasdaq: CASI) is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. We were incorporated in 1991, and in 2012, with new leadership, we shifted our business strategy to China and have since built an infrastructure in China that includes sales and marketing, medical affairs, regulatory and clinical development and in the foreseeable future, manufacturing. We are focused on acquiring, developing and commercializing products that augment our hematology oncology therapeutic focus as well as other areas of unmet medical need. We are executing our plan to become a biopharmaceutical leader by launching medicines in the greater China market, leveraging our China-based regulatory, clinical and commercial competencies and utilizing our global drug development expertise. The majority of our operations and activities are now located in China and are conducted primarily through two of our subsidiaries: (i) CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is wholly owned and is located in Beijing, China, and (ii) CASI Pharmaceuticals (Wuxi) Co., Ltd. (“CASI Wuxi”), which is located in Wuxi, China. Our Beijing office is primarily responsible for our day-to-day operations, and our commercial team of over 130 hematology/oncology sales and marketing specialists is based throughout China. CASI Wuxi is part of the long-term strategy to support our future clinical and commercial manufacturing needs, to manage our supply chain for certain products, and to develop a GMP manufacturing facility in China.
We launched our first commercial product, EVOMELA® (Melphalan for Injection) in China in August 2019. In China, EVOMELA® is approved for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The other core hematology/oncology assets in our pipeline include:
| ● | CNCT19 is an autologous CD19 CAR-T investigative product (“CNCT19”) being developed by our partner Juventas Biotechnology (Tianjin) Co., Ltd. (“Juventas”) for which we have exclusive worldwide co-commercial and profit-sharing rights. CNCT19 is being developed as a potential treatment for patients with hematological malignancies which express CD19 including, B-cell acute lymphoblastic leukemia (“B-ALL”) and B-cell non-Hodgkin lymphoma (“B-NHL”). Juventas has completed the CNCT19 Phase 1 studies in patients with B-ALL and B-NHL, and has completed the Phase 2 B-ALL pivotal study in China, the B-NHL registration study is still ongoing in China. |
| ● | In October 2020, the Company entered into an exclusive licensing agreement with BioInvent International AB (“BioInvent”) for the development and commercialization of novel anti-FcγRIIB antibody, BI-1206, in Mainland China, Taiwan, Hong Kong and Macau. BioInvent is a biotechnology company focused on the discovery and development of first-in-class immune-modulatory antibodies for cancer immunotherapy. BI-1206 is being investigated in a Phase 1/2 trial, in combination with anti-PD1 therapy Keytruda® (pembrolizumab), in patients with solid tumors, and in a Phase 1/2a trial in combination with MabThera® (rituximab) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). Clinical Trial Application (CTA) was approved by China National Medical Products Administration (NMPA) in December 2021 and ethics committee approvals have been received in January of 2022. The Company obtained approval from Human Genetic Resources Administration of China (“HGRAC”) in April 2022. The Company is planning a Phase 1 study of BI-1206 in combination with rituximab with a single agent BI-1206 run in phase in patients with NHL (mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma) to assess PK, safety and tolerability, select the Recommended Phase 2 Dose and assess early signs of clinical efficacy as part of its development program for BI-1206 in China. The study received regulatory approval from the China Center for Drug Evaluation (“CDE”) in the second quarter of 2022, and the first patient was enrolled and dosed in the third quarter of 2022. |
| ● | CB-5339 is a novel VCP/p97 inhibitor focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies. We entered into an exclusive license on March 21, 2021 with Cleave Therapeutics, Inc. (“Cleave”) for the development and commercialization of CB-5339 in Mainland China, Hong Kong, Macau and Taiwan. CB-5339, an oral second-generation, small molecule VCP/p97 inhibitor, is being evaluated in a Phase 1 clinical trial in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The CDE has responded to CB-5339 CTA application for the multiple myeloma indication submitted in March 2022 and the Company has completed and submitted its response to the CDE. |
23
| ● | CID-103 is a full human IgG1 anti-CD38 monoclonal antibody recognizing a unique epitope that has demonstrated an encouraging preclinical efficacy and safety profile compared to other anti-CD38 monoclonal antibodies, and which we have exclusive global rights. CID-103 is being developed for the treatment of patients with multiple myeloma. The Phase 1 dose escalation and expansion study of CID-103, in patients with previously treated, relapsed or refractory multiple myeloma is ongoing in France and the UK. |
CASI has built a fully integrated, world class biopharmaceutical company dedicated to the successful development and commercialization of innovative and other therapeutic products. Our business development strategy is currently focused on acquiring additional targeted drugs and immuno-oncology therapeutics through licensing that will expand our hematology/oncology franchise. We use a market-oriented approach to identify pharmaceutical/biotechnology candidates that we believe to have the potential for gaining widespread market acceptance, either globally or in China, and for which development can be accelerated under our global drug development strategy. In many cases our business development strategy includes direct equity investments in the licensor company. We intend for our pipeline to reflect a diversified and risk-balanced set of assets that include (1) late-stage clinical drug candidates in-licensed for China or global regional rights, (2) proprietary or licensed innovative drug candidates, and (3) select high quality pharmaceuticals that fit our therapeutic focus. We have focused on US/EU approved product candidates, and product candidates with proven targets or product candidates that have reduced clinical risk with a greater emphasis on innovative therapeutics. Although oncology with a focus on hematological malignancies is our principal clinical and commercial target, we are opportunistic about other therapeutic areas that can address unmet medical needs. We will continue to pursue building a robust pipeline of drug candidates for development and commercialization in China as our primary market, and if rights are available for the rest of the world.
We believe our China operations offer a significant market and growth potential due to the extraordinary increase in demand for high quality medicines coupled with regulatory reforms in China that facilitate the entry of new pharmaceutical products into the country. We will continue to in-license clinical-stage and late-stage drug candidates, and leverage our cross-border operations and expertise, and hope to be the partner of choice to provide access to the China market. We expect the implementation of our plans will include leveraging our resources and expertise in both the U.S. and China so that we can maximize regulatory, development and clinical strategies in both countries.
Our commercial product, EVOMELA®, was originally licensed from Spectrum Pharmaceuticals, Inc. (“Spectrum”) and we had a supply agreement with Spectrum to support our application for import drug registration and for commercialization purposes. Spectrum completed the sale of its portfolio of FDA-approved hematology/oncology products including EVOMELA® to Acrotech Biopharma L.L.C. (“Acrotech”) on March 1, 2019. The original supply agreement with Spectrum was assumed by Acrotech.
As part of the long-term strategy to support our future clinical and commercial manufacturing needs and to manage our supply chain for certain products, on December 26, 2018, we established CASI Wuxi, between the Company and Wuxi Jintou Huicun Investment Enterprise, a limited partnership (“Wuxi LP”). To develop a GMP manufacturing facility, CASI Wuxi entered into a lease agreement of a state-owned land in 2019, a lease agreement of a manufactory building in 2020, and a series of contracts for construction and equipment since 2020.
In 2020, the worldwide outbreak of the COVID-19 pandemic adversely impacted our EVOMELA® marketing and sales activities as well as the supply chain for EVOMELA®. We currently rely on a single source for the supply of EVOMELA®. The continuation of the COVID-19 pandemic or the emergence of new COVID-19 variants or new pandemics may affect the economies and financial markets of many countries, which may result in a period of economic slowdown or recessions. In such an event, our ability to continue to commercialize and expand distribution of EVOMELA® could be adversely affected if the supplier refuses or is unable to provide products for any reason, which would likely interrupt the manufacturing of EVOMELA®, cause supply chain delays and increase costs. Early in the COVID-19 pandemic, we experienced a disruption to our supply chain for EVOMELA®, we have not experienced supply disruption in 2021 and the first three quarters of 2022; however, there can be no assurance that we will not experience supply disruption again for EVOMELA® during the emergence of new COVID-19 variants.
In 2021, the COVID-19 pandemic in China has been effectively contained by the prompt and effective governmental control measures, and we have experienced minimal disruption to our business activities. However, due to the outbreak of Omicron and other variants of COVID-19 in the second quarter of 2022, the lockdown in Shanghai and restrictions in other major cities in China led to limitation of access to local hospitals, which had an adverse impact on the sales of EVOMELA® for the second and the third quarters. The restrictions also adversely impacted the enrollment of patients for the CNCT19 Phase II registration studies. Recently, the pandemic
24
gradually spread nationwide in China, and many small and medium-sized cities have been upgrading their control measures ever since the third quarter. These series of control measures are expected to adversely impact our sales activities for the remainder of 2022. Given that such COVID-19 related restrictions are beyond our control, at this stage, it is unable to assess how long such COVID-19 related restrictions may continue in China, and the full extent to which such restrictions may directly and indirectly impact our business operations. Considering the uncertainty of the development of COVID-19 pandemic, we will continue to pay close attention to the development of the COVID-19 pandemic and dedicate resources to take any necessary measures in a timely manner to minimize the unfavorable impact on our businesses and operations.
RESULTS OF OPERATIONS
Operating Items
Revenues
Product Sales
Product sales consist of sales of EVOMELA® that launched during August 2019. Revenue was $10.2 million and $27.8 million, respectively, for the three and nine months ended September 30, 2022, compared to $8.1 million and $20.9 million, respectively, for the corresponding periods in 2021. Revenues increased by 26% and 33%, respectively, for the three and nine months ended September 30, 2022 as compared to the corresponding periods of 2021 due to the continued growth in EVOMELA® sales.
Lease Income
Lease income consists primarily of an equipment lease with Juventas. Lease income was nil and $60,000, respectively, for the three and nine months ended September 30, 2022, compared to $37,000 and $110,000, respectively, for the corresponding periods in 2021.
Operating Expenses
Cost of Revenues
Cost of revenues consists primarily of the cost of inventories of EVOMELA® and sales-based royalties related to the sale of EVOMELA®.
Costs of revenues were $4.2 million and $11.6 million, respectively, for the three and nine months ended September 30, 2022, compared to $3.4 million and $8.8 million, respectively, for the corresponding periods in 2021. Gross profit was around 58% for all the four periods, which was stable.
Research and Development Expenses
Research and development (R&D) expenses consist primarily of compensation and other expenses related to research and development personnel, research collaborations, costs associated with internal and contract preclinical testing and clinical trials of our product candidates, including the costs of drug substance and drug product, regulatory maintenance costs of ANDAs, facilities expenses, and amortization expense of acquired ANDAs.
Research and development expenses were $3.9 million and $11.7 million, respectively, for the three and nine months ended September 30, 2022, compared to $2.9 million and $10.4 million, respectively, for the corresponding periods in 2021. The increase of research and development expenses for the three months periods was mainly due to expense incurred for BI-1206 and CID-103.
General and Administrative Expenses
General and administrative expenses include compensation and other expenses related to executive, finance, business development and administrative personnel, professional services, investor relations and facilities.
25
General and administrative expenses were $4.8 million and $15.7 million, respectively, for the three and nine months ended September 30, 2022, compared to $5.3 million and $16.2 million, respectively, for the corresponding periods in 2021. The decrease in general and administrative expenses was mainly due to the decrease in professional fee.
Selling and Marketing Expenses
Selling and marketing expenses are the direct costs related to the sales of EVOMELA® that was launched in China in August 2019, such as sales force salaries, bonuses, advertising, and other marketing efforts.
Selling and marketing expenses were $3.6 million and $10.2 million, respectively, for the three and nine months ended September 30, 2022, compared to $3.4 million and $9.5 million, respectively, for the corresponding periods in 2021. The increase in selling and marketing expenses was due to the increase of sales commission in accordance with the increase in sales of EVOMELA® and expansion of sales team in China.
Acquired in-process Research and Development
There were no acquired in-process R&D expenses for the three and nine months ended September 30, 2022. Acquired in-process R&D expenses for the three and nine months ended September 30, 2021 were nil and $6.6 million, respectively. Among the total $6.6 million, $5.5 million was related to the upfront payment to Cleave for the development of CB-5339, and $1.1 million was related to the milestone payment for the development of CID-103.
Non-Operating Items
Interest (expense)/income, net
Interest (expense)/income, net was expense of $13,000 and income of $101,000, respectively, for the three and nine months ended September 30, 2022, compared to $79,000 and $261,000, respectively, for the corresponding periods in 2021.
Other income
Other income was $11,000 and $60,000, respectively, for the three and nine months ended September 30, 2022, compared to $487,000 and $540,000, respectively, for the corresponding periods in 2021. Other income recognized in 2022 was mainly related to the amortized government grant. Other income recognized in the third quarter of 2021 mainly related to the loan to the Company under the Paycheck Protection Program (PPP) that was forgiven in September 2021.
Foreign exchange gains/(losses)
Foreign exchange gains were $0.6 million and $2.3 million, respectively, for the three and nine months ended September 30, 2022, compared to losses of $6,000 and gains of $289,000, respectively, for the corresponding periods in 2021. The foreign exchange gains were primarily due to accounts receivable with CRPCGIT and USD denominated cash accounts that are held by our Chinese subsidiaries.
Change in fair value of investments
The changes in fair value of investments for the three and nine months ended September 30, 2022 were gains of $0.7 million and losses of $2.0 million, respectively, compared to losses of $3.7 million and $0.2 million, respectively, for the corresponding periods in 2021. The changes represent unrealized gains or losses on the Company’s investments in equity securities and long-term investments. The changes were mainly due to the fluctuations in the market price of two publicly traded companies invested by us.
Impairment loss of long-term investments
There was no impairment loss of long-term investments during the three and nine months ended September 30, 2022. Impairment loss of long-term investments for the three and nine months ended September 30, 2021 was nil and $0.9 million, respectively. The loss was related to the investment in Black Belt Tx.
26
LIQUIDITY AND CAPITAL RESOURCES
To date, the Company has been engaged primarily in research and development activities. As a result, the Company has incurred and expect to continue to incur operating losses in 2022 and the foreseeable future.
The Company will require significant additional funding to fund operations beyond the third quarter of 2023 until such time, if ever, it becomes profitable. The Company intends to augment its cash balances by pursuing other forms of capital infusion, including strategic alliances or collaborative development opportunities with organizations that have capabilities and/or products that are complementary to its capabilities and products in order to continue the development of its potential product candidates that they intend to pursue to commercialization. If the Company seeks strategic alliances, licenses, or other alternative arrangements, such as arrangements with collaborative partners or others, to raise further financing, it may need to relinquish rights to certain of its existing product candidates, or products they would otherwise seek to develop or commercialize on its own, or to license the rights to its product candidates on terms that are not favorable to it.
The Company also invested in its development of the Wuxi land and construction of the manufacturing building. Commencing from the fourth quarter of 2020, in relation to the development of the Wuxi land and construction of the manufacturing building, the Company entered into a series of contracts for the development and construction work. Total commitment under these contracts was RMB 59.2 million (approximately $8.3 million) as of September 30, 2022.
The Company will continue to seek to raise additional capital to fund its commercialization efforts, expansion of its operations, capital expenditure, research and development, and for the acquisition of new product candidates, if any. The Company intends to and is currently actively communicating to explore one or more of the following alternatives to raise additional capital:
| ● | raising bank loans; |
| ● | selling additional equity securities; |
| ● | out-licensing product candidates to one or more corporate partners; |
| ● | completing an outright sale of non-priority assets; and/or |
| ● | engaging in one or more strategic transactions. |
The Company also will continue to manage its cash resources prudently and cost-effectively.
There can be no assurance that adequate additional financing under such arrangements will be available to the Company on terms that they deem acceptable, if at all. If additional funds are raised by issuing equity securities, dilution to existing stockholders may result, or the equity securities may have rights, preferences, or privileges senior to those of the holders of its common stock. If they fail to obtain additional capital when needed, they may be required to delay or scale back their commercialization efforts, advancement of the Spectrum products or plans for other product candidates, if any.
Since its inception in 1991, the Company has incurred significant losses from operations and, as of September 30, 2022, had incurred an accumulated deficit of $624.9 million. The Company believes that it has sufficient resources to fund its operations at least one year beyond the date that the interim consolidated financial statements are issued for the period ended September 30, 2022.
FINANCING ACTIVITIES
Bank Borrowings
In May 2022, the Company entered into a Business Loan Agreement (together with related security agreements and promissory note, the “Agreement”) with East West Bank (“EWB”). Under the Agreement, EWB made available to the Company a revolving line of credit up to a maximum of $10.0 million. The Agreement will mature on December 31, 2022, unless extended to April 30, 2024 subject to certain conditions as defined in the Agreement. In general, amounts borrowed under the Agreement are secured by a lien on the Company’s assets, including first priority security interest in accounts receivable and inventory and pledge of available-for-sale securities. Under the Agreement, the Company shall maintain at least $2.5 million cash on deposit at EWB. EWB shall, when certain conditions are met, partially or fully release this cash deposit requirement. Amounts borrowed under the Agreement bear interest, payable
27
monthly. Interest shall accrue based upon the daily Wall Street Journal Prime Rate (as quoted in the “Money Rates” column of The Wall Street Journal (Western Edition)) plus 0.35% with a floor rate of 3.85%. Interest is calculated by applying the ratio of the interest rate over a year of 360 days, multiplied by the outstanding principal balance, multiplied by the actual number of days the principal balance is outstanding. As of September 30, 2022, the outstanding principal balance under this agreement was $3.0 million.
In June 2022, the Company’s subsidiary, CASI China entered into a Loan Agreement with China International Trust and Investment Corporation Bank (“CITIC Bank”). Under the Loan Agreement, CITIC Bank made available to CASI China a guaranteed line of credit up to a maximum of RMB 20.0 million (approximately $3.0 million). The Loan Agreement will mature on June 13, 2023. The joint and several liability guarantee was provided by Beijing Shouchuang Financing Guarantee Co. Ltd. concurrently with the Loan Agreement. The loan was secured by a pledge of the land use right held by CASI Wuxi. Interest accrues on the principal amounts of the loans outstanding at an fixed annual rate of 3.98% and payable monthly. In the second quarter of 2022, CASI China made a drawdown under the loan amounted to RMB 6.7 million ($1.0 million) and repaid all the outstanding principal balance and interest in the third quarter of 2022. The Loan Agreement was terminated in July 2022 and the land use right was released from the pledge in September 2022.
Stock Repurchase Program
On December 15, 2021, our board of directors approved a stock repurchase program for the repurchase of up to $10 million of our common stock (and no more than 12,500,000 shares of our common stock, not adjusted to reflect the Reverse Stock Split) through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934 and through trading plans established pursuant to Rule 10b5-1 of the Securities Exchange from time to time. The Company established a Rule 10b5-1 trading plan to carry out the stock repurchase, which was terminated on March 31, 2022, and as of the termination date, we had repurchased 3,734,992 shares of Common Stock (among which 2,541,245 shares of Common Stock were retired, not adjusted to reflect the Reverse Stock Split) amounted to $3.0 million.
INTEREST RATE CHANGES
Management does not believe that our working capital needs are sensitive to changes in interest rates.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Based on an evaluation under the supervision and with the participation of our management, our Chief Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) were effective as of September 30, 2022 to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
We believe that a controls system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.
28
Changes in Internal Control Over Financial Reporting
There have not been any changes in our internal control over financial reporting during the quarter ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
We are subject in the normal course of business to various legal proceedings in which claims for monetary or other damages may be asserted. Management does not believe such legal proceedings, unless otherwise disclosed herein, are material.
ITEM 1A. RISK FACTORS
For information regarding factors that could affect the Company’s results of operations, financial condition and liquidity, see the risk factors discussion set forth in Item 1A of CASI’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, Quarterly Report on Form 10-Q for the three months ended June 30, 2022, and the information under “Special Note Regarding Forward-Looking Statements” included in this report. Other than disclosed herein, there have been no material changes to our risk factors from those disclosed in our Quarterly Report on Form 10-Q for the three months ended June 30, 2022.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
Not applicable.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
Not applicable.
29
ITEM 6. EXHIBITS
10.1* ˄ |
| |
31.1* | | |
31.2* | | |
32.1** | | |
32.2** | | |
101.INS | | Inline XBRL Instance Document. The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document. |
101.SCH | | Inline XBRL Taxonomy Extension Schema Document. |
101.CAL | | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
101.DEF | | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
101.LAB | | Inline XBRL Taxonomy Extension Label Linkbase Document. |
101.PRE | | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
104 | | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101 filed herewith). |
**Furnished Herewith
˄ Certain confidential information contained in this exhibit has been omitted because it (i) is not material and (ii) would be competitively harmful if publicly disclosed.
30
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | ||
|
| CASI PHARMACEUTICALS, INC. | |
| | (Registrant) | |
| |
|
|
| |
| |
Date: November 14, 2022 | | /s/ Wei-Wu He | |
| | | |
| | Chief Executive Officer | |
| |
| |
| |
| |
Date: November 14, 2022 | | | |
| | | |
| | Principal Financial Officer | |
31
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 4/30/24 | ||||
| 6/13/23 | ||||
| 12/31/22 | ||||
| 12/15/22 | ||||
| Filed on: | 11/14/22 | |||
| 11/8/22 | ||||
| For Period end: | 9/30/22 | |||
| 6/30/22 | 10-Q | |||
| 6/2/22 | ||||
| 6/1/22 | ||||
| 5/26/22 | 4, 8-K | |||
| 3/31/22 | 10-Q | |||
| 12/31/21 | 10-K | |||
| 12/15/21 | ||||
| 9/30/21 | 10-Q | |||
| 6/30/21 | 10-Q | |||
| 3/31/21 | 10-Q | |||
| 3/21/21 | ||||
| 12/31/20 | 10-K, 10-K/A | |||
| 12/15/19 | 4 | |||
| 10/29/19 | 8-K | |||
| 7/1/19 | ||||
| 3/1/19 | ||||
| 12/26/18 | ||||
| 12/15/18 | ||||
| 12/3/18 | 4, 8-K | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/28/24 CASI Pharmaceuticals, Inc. 20-F 12/31/23 142:21M Toppan Merrill Bridge/FA 4/26/23 CASI Pharmaceuticals, Inc. 20-F 12/31/22 129:16M Toppan Merrill Bridge/FA 4/26/23 CASI Pharmaceuticals, Inc. (DE) 20-F 12/31/22 129:16M Toppan Merrill Bridge/FA 3/21/23 CASI Pharmaceuticals, Inc. (DE) S-8 POS 3/21/23 3:172K Toppan Merrill/FA 3/21/23 CASI Pharmaceuticals, Inc. (DE) S-8 POS 3/21/23 3:172K Toppan Merrill/FA 3/21/23 CASI Pharmaceuticals, Inc. (DE) S-8 POS 3/21/23 3:172K Toppan Merrill/FA 3/21/23 CASI Pharmaceuticals, Inc. (DE) S-8 POS 3/21/23 3:172K Toppan Merrill/FA 2/14/23 CASI Pharmaceuticals, Inc. 424B3 1:1.7M Toppan Merrill/FA 2/14/23 CASI Pharmaceuticals, Inc. (DE) DEF 14A 3/20/23 1:1.7M Toppan Merrill/FA 2/09/23 CASI Pharmaceuticals, Inc. F-4/A 1:924K Toppan Merrill/FA 1/31/23 CASI Pharmaceuticals, Inc. F-4 22:2.7M Toppan Merrill/FA |